Patents by Inventor Gilles H. Tapolsky

Gilles H. Tapolsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220089606
    Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.
    Type: Application
    Filed: December 1, 2021
    Publication date: March 24, 2022
    Inventors: James D. McChesney, Gilles H. Tapolsky, David Lloyd Emerson, John Marshall, Michael Kurman, Manuel R. Modiano
  • Patent number: 11220512
    Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: January 11, 2022
    Assignee: Tapestry Pharmaceuticals, Inc.
    Inventors: James D. McChesney, Gilles H. Tapolsky, David Lloyd Emerson, John Marshall, Michael Kurman, Manuel R. Modiano
  • Publication number: 20210401797
    Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
    Type: Application
    Filed: September 9, 2021
    Publication date: December 30, 2021
    Applicant: TAPESTRY PHARMACEUTICALS, INC.
    Inventors: James D. MCCHESNEY, Gilles H. TAPOLSKY, David L. EMERSON, John MARSHALL, Michael KURMAN, Manuel MODIANO
  • Patent number: 11147793
    Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubules at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: October 19, 2021
    Assignee: TAPESTRY PHARMACEUTICALS, INC.
    Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
  • Publication number: 20200347076
    Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.
    Type: Application
    Filed: July 15, 2020
    Publication date: November 5, 2020
    Inventors: James D. McChesney, Gilles H. Tapolsky, David LLoyd Emerson, John Marshall, Michael Kurman, Manuel R. Modiano
  • Patent number: 10745408
    Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: August 18, 2020
    Assignee: Tapestry Pharmaceuticals, Inc.
    Inventors: James D. McChesney, Gilles H. Tapolsky, David Lloyd Emerson, John Marshall, Michael Kurman, Manuel R. Modiano
  • Publication number: 20200002351
    Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.
    Type: Application
    Filed: September 12, 2019
    Publication date: January 2, 2020
    Inventors: James D. McChesney, Gilles H. Tapolsky, David Lloyd Emerson, John Marshall, Michael Kurman, Manuel R. Modiano
  • Patent number: 10450323
    Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: October 22, 2019
    Assignee: TAPESTRY PHARMACEUTICALS, INC.
    Inventors: James D. McChesney, Gilles H. Tapolsky, David Lloyd Emerson, John Marshall, Michael Kurman, Manuel R. Modiano
  • Publication number: 20190046501
    Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubules at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
    Type: Application
    Filed: October 12, 2018
    Publication date: February 14, 2019
    Applicant: TAPESTRY PHARMACEUTICALS, INC.
    Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
  • Patent number: 10143677
    Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: December 4, 2018
    Assignee: TAPESTRY PHARMACEUTICALS, INC.
    Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
  • Patent number: 10010542
    Abstract: A novel compound, (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one, is provided herein. (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one is an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) with surprisingly superior efficacy and pharmacodynamic properties in vitro and in vivo. Also provided are pharmaceutical compositions including the compound and methods of use of the compound in treating cancer and tumors in vivo, as well as inhibiting glycolytic flux and PFKFB3 enzymatic activity in cells.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: July 3, 2018
    Assignee: GB ACT, INC.
    Inventors: Gilles H. Tapolsky, Pooran Chand
  • Publication number: 20180117002
    Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
    Type: Application
    Filed: April 10, 2017
    Publication date: May 3, 2018
    Applicant: Tapestry Pharmaceuticals, Inc.
    Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
  • Publication number: 20180105535
    Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.
    Type: Application
    Filed: October 30, 2017
    Publication date: April 19, 2018
    Inventors: James D. McChesney, Gilles H. Tapolsky, David Lloyd Emerson, John Marshall, Michael Kurman, Manuel R. Modiano
  • Patent number: 9802951
    Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: October 31, 2017
    Assignee: Tapestry Pharmaceuticals, Inc.
    Inventors: James D. McChesney, Gilles H. Tapolsky, David Lloyd Emerson, John Marshall, Michael Kurman, Manuel R. Modiano
  • Publication number: 20170273942
    Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
    Type: Application
    Filed: April 10, 2017
    Publication date: September 28, 2017
    Applicant: Tapestry Pharmaceuticals, Inc.
    Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
  • Publication number: 20170258783
    Abstract: A novel compound, (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one, is provided herein. (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one is an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) with surprisingly superior efficacy and pharmacodynamic properties in vitro and in vivo. Also provided are pharmaceutical compositions including the compound and methods of use of the compound in treating cancer and tumors in vivo, as well as inhibiting glycolytic flux and PFKFB3 enzymatic activity in cells.
    Type: Application
    Filed: April 10, 2017
    Publication date: September 14, 2017
    Inventors: Gilles H. Tapolsky, Pooran Chand
  • Patent number: 9649305
    Abstract: A novel compound, (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one, is provided herein. (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one is an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) with surprisingly superior efficacy and pharmacodynamic properties in vitro and in vivo. Also provided are pharmaceutical compositions including the compound and methods of use of the compound in treating cancer and tumors in vivo, as well as inhibiting glycolytic flux and PFKFB3 enzymatic activity in cells.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 16, 2017
    Assignee: Advanced Cancer Therapeutics, LLC
    Inventors: Gilles H. Tapolsky, Pooran Chand
  • Publication number: 20160281090
    Abstract: Oligonucleotides according to the following Formula I are provided herein: 5?-Xa-Q-Yb-3? wherein X and Y are each independently selected from the group consisting of a lipid and a polyethylene glycol; Q is a quadruplex-forming guanine-rich promoter gene oligonucleotide (GPGO); a is 0 or 1; and b is 0 or 1, wherein the sum of a+b=1 or 2. Also provided are compositions including Formula I oligonucleotides and methods of their use in inhibiting cell growth, treating cancer, and treating tumors.
    Type: Application
    Filed: November 6, 2014
    Publication date: September 29, 2016
    Applicant: Advanced Cancer Therapeutics, LLC
    Inventor: Gilles H. Tapolsky
  • Patent number: 9403769
    Abstract: Small molecule inhibitors of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) having the following formula: Formula (1) are provided herein. Also provided herein are pharmaceutical compositions containing Formula I compounds, together with methods of treating cancer, methods of inhibiting PFK.FB3 enzymatic activity, methods of inhibiting glycolytic flux, and methods of treating tumors by administering an effective amount of a Formula I compound.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: August 2, 2016
    Assignees: Advanced Cancer Therapeutics, LLC, University of Louisville Research Foundation, Inc.
    Inventors: Pooran Chand, Jason A. Chesney, Brian F. Clem, Gilles H. Tapolsky, Sucheta Telang, John O. Trent
  • Publication number: 20160101061
    Abstract: The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized drug delivery and protection to the treatment site. The kinetics of erodability are easily adjusted by varying the number of layers and/or the components.
    Type: Application
    Filed: August 19, 2015
    Publication date: April 14, 2016
    Inventors: Gilles H. Tapolsky, David W. Osborne